Virbac SA (EPA:VIRP)

Market Cap	2.97B -0.1%
Revenue (ttm)	1.49B +4.3%
Net Income	155.85M +17.2%
EPS	18.58 +17.0%
Shares Out	8.38M
PE Ratio	19.05
Forward PE	16.50
Dividend	1.45 (0.41%)
Ex-Dividend Date	Jul 2, 2026

Volume	2,547
Open	345.00
Previous Close	347.00
Day's Range	343.00 - 354.00
52-Week Range	297.00 - 389.50
Beta	0.75
Analysts	Strong Buy
Price Target	412.29 (+16.47%)
Est. Earnings	Mar 17, 2027

About Virbac

Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific. The company offers Vikaly, a cat food designed for the management of feline chronic kidney disease; Prevexto that contains imidacloprid and flumethrin, providing long-lasting parasite protection collar for dogs and cats at risk of fleas, ticks, lice, and sandflies; Zenidog/Zenifel offers a fogger, spray, and non-electric ph...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1968
• Employees: 6,442
• Stock Exchange: Euronext Paris
• Ticker Symbol: VIRP

Financial Performance

In 2025, Virbac's revenue was 1.46 billion, an increase of 4.82% compared to the previous year's 1.40 billion. Earnings were 150.89 million, an increase of 3.85%.

Analyst Summary

According to 7 analysts, the average rating for VIRP stock is "Strong Buy." The 12-month stock price target is €412.29, which is an increase of 16.47% from the latest price.

Price Target

€412.29

(16.47% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 2, 2026

Data Sources Report a data error